Clinical Laserthermia Systems AB (publ) (STO:CLS.B)
Sweden
· Delayed Price · Currency is SEK 2.780
-0.050 (-1.77%)
Jun 9, 2025, 3:39 PM CET
STO:CLS.B Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 20.14 | 18.78 | 8.27 | 6.27 | 2.25 | 1.33 | Upgrade
|
| Revenue | 20.14 | 18.78 | 8.27 | 6.27 | 2.25 | 1.33 | Upgrade
|
| Revenue Growth (YoY) | 86.02% | 127.04% | 31.99% | 179.20% | 68.54% | -75.79% | Upgrade
|
| Cost of Revenue | 6.16 | 8.36 | 5.28 | 9.06 | 5.88 | 0.46 | Upgrade
|
| Gross Profit | 13.98 | 10.42 | 3 | -2.79 | -3.63 | 0.88 | Upgrade
|
| Selling, General & Admin | 56.55 | 62.04 | 66.13 | 62.29 | 54.2 | 49.77 | Upgrade
|
| Other Operating Expenses | 0.42 | 0.49 | -0.36 | -0.09 | -0 | 0.01 | Upgrade
|
| Operating Expenses | 59.64 | 65.2 | 68.48 | 64.65 | 56.98 | 52.83 | Upgrade
|
| Operating Income | -45.67 | -54.78 | -65.48 | -67.44 | -60.61 | -51.96 | Upgrade
|
| Interest Expense | -0.48 | -0.43 | -9.76 | -10.97 | -6.41 | -3.27 | Upgrade
|
| Interest & Investment Income | 2.4 | 6.83 | 0.3 | 7.4 | 2.91 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.45 | -0 | -0.07 | -0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.54 | 0.53 | 0 | -0.22 | 0.03 | 0.19 | Upgrade
|
| EBT Excluding Unusual Items | -43.21 | -47.86 | -75.39 | -71.24 | -64.14 | -55.33 | Upgrade
|
| Gain (Loss) on Sale of Investments | -7.31 | - | -5.48 | -0.03 | - | -2.61 | Upgrade
|
| Pretax Income | -50.52 | -47.86 | -80.88 | -71.27 | -64.14 | -57.94 | Upgrade
|
| Earnings From Continuing Operations | -50.52 | -47.86 | -80.88 | -71.27 | -64.14 | -57.94 | Upgrade
|
| Minority Interest in Earnings | 0.07 | 0.24 | 1.08 | 0.61 | 0.53 | - | Upgrade
|
| Net Income | -50.45 | -47.62 | -79.79 | -70.66 | -63.62 | -57.94 | Upgrade
|
| Net Income to Common | -50.45 | -47.62 | -79.79 | -70.66 | -63.62 | -57.94 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 11 | 3 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 11 | 3 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 204.91% | 227.83% | 705.35% | 45.02% | 30.24% | 27.46% | Upgrade
|
| EPS (Basic) | -3.43 | -4.33 | -23.76 | -169.43 | -221.20 | -262.38 | Upgrade
|
| EPS (Diluted) | -3.43 | -4.33 | -23.76 | -169.43 | -221.20 | -262.38 | Upgrade
|
| Free Cash Flow | -48.02 | -58.92 | -68.6 | -82.1 | -66.32 | -55.76 | Upgrade
|
| Free Cash Flow Per Share | -3.27 | -5.35 | -20.42 | -196.85 | -230.61 | -252.49 | Upgrade
|
| Gross Margin | 69.40% | 55.47% | 36.23% | -44.51% | -161.69% | 65.77% | Upgrade
|
| Operating Margin | -226.75% | -291.65% | -791.49% | -1075.95% | -2699.97% | -3900.75% | Upgrade
|
| Profit Margin | -250.51% | -253.54% | -964.49% | -1127.31% | -2833.63% | -4349.78% | Upgrade
|
| Free Cash Flow Margin | -238.44% | -313.67% | -829.18% | -1309.76% | -2954.16% | -4185.81% | Upgrade
|
| EBITDA | -43 | -52.11 | -65.14 | -67.05 | -59.93 | -51.27 | Upgrade
|
| EBITDA Margin | -213.49% | -277.43% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.67 | 2.67 | 0.34 | 0.39 | 0.68 | 0.69 | Upgrade
|
| EBIT | -45.67 | -54.78 | -65.48 | -67.44 | -60.61 | -51.96 | Upgrade
|
| EBIT Margin | -226.75% | -291.65% | - | - | - | - | Upgrade
|
| Revenue as Reported | - | - | - | - | 2.41 | 2.55 | Upgrade
|
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.